DNA Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1830214 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-33.1%
TTM net income YoY26.1%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-242.5%
Net margin-249.2%
FCF margin-172.3%
EBITDA margin-190.5%
Returns
ROE-52.7%
ROA-23.5%
ROIC (approx.)-51.0%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets58.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue6.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $170.16M | $227.04M | $251.46M | $477.71M | $313.84M |
| R&D expense | $243.77M | $424.06M | $580.62M | $1.05B | $1.15B |
| SG&A expense | $183.29M | $246.16M | $385.02M | $1.43B | $862.95M |
| Operating income | -$315.28M | -$559.76M | -$864.41M | -$2.21B | -$1.83B |
| Interest expense | $0 | $94,000 | $93,000 | $106,000 | $2.37M |
| Pretax income | -$313.60M | -$547.51M | -$892.94M | -$2.12B | -$1.84B |
| Income tax | -$837,000 | -$479,000 | -$71,000 | -$15.03M | -$1.48M |
| Net income | -$312.76M | -$547.03M | -$892.87M | -$2.10B | -$1.83B |
| EBITDA | -$256.29M | -$496.74M | -$793.90M | -$2.17B | -$1.80B |
| EPS (basic) | -5.64 | -10.54 | -18.37 | -50.15 | -1.35 |
| EPS (diluted) | -5.64 | -10.54 | -18.37 | -50.20 | -1.39 |
| Weighted avg. shares (diluted) | 55.46M | 51.89M | 48.61M | 42.00M | 1.36B |
| Banking | |||||
| Net interest income | — | — | — | — | -$9.65M |
| Loans, net | $9.70M | $25.10M | $21.00M | $7.50M | — |
| Balance sheet | |||||
| Cash & equivalents | $167.20M | $561.57M | $944.07M | $1.32B | $1.55B |
| Short-term investments | $255.42M | $0 | — | — | — |
| Receivables | $24.03M | $21.86M | $17.16M | $80.91M | $131.54M |
| Inventory | — | — | $46,000 | $4.36M | $3.36M |
| Current assets | $471.84M | $602.74M | $1.00B | $1.45B | $1.72B |
| PP&E, net | $167.37M | $203.72M | $188.19M | $314.77M | $145.77M |
| Goodwill | — | $0 | $49.24M | $60.21M | $21.31M |
| Intangibles | $53.48M | $72.51M | $82.74M | $111.04M | $21.64M |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B |
| Current liabilities | $95.97M | $107.27M | $163.86M | $172.96M | $134.76M |
| Total liabilities | $611.11M | $661.39M | $568.19M | $803.04M | $503.61M |
| Shareholders' equity | $508.59M | $716.06M | $1.10B | $1.74B | $1.51B |
| Shares outstanding | 58.21M | 54.37M | 50.03M | 1.89B | 1.61B |
| Cash flow statement | |||||
| Operating cash flow | -$171.06M | -$319.58M | -$295.50M | -$252.20M | -$253.82M |
| Capital expenditure | $7.67M | $62.54M | $40.80M | $52.27M | $56.52M |
| Free cash flow | -$178.72M | -$382.13M | -$336.30M | -$304.47M | -$310.34M |
| Investing cash flow | -$240.29M | -$62.24M | -$80.69M | -$67.39M | -$73.26M |
| Financing cash flow | $17.77M | -$1.74M | -$3.22M | $95.34M | $1.53B |
| Depreciation & amortization | $58.99M | $63.02M | $70.51M | $42.55M | $29.08M |
| Stock-based compensation | $81.55M | $112.34M | $229.88M | $1.93B | $1.61B |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.